Home / Health / University of Alabama at Birmingham Hospital, one of 75 locations worldwide participating in clinical trial for COVID-19 treatment

University of Alabama at Birmingham Hospital, one of 75 locations worldwide participating in clinical trial for COVID-19 treatment



The University of Alabama at Birmingham announced on Thursday that its hospital is one of 75 locations worldwide to participate in a clinical trial for COVID-19 treatment. The National Institute of Allergy and Infectious Diseases activated the site at Birmingham Hospital on Wednesday, which means the hospital can register in the trial immediately. The first drug to be evaluated for treatment is remdesivir. Health representatives have not released any other drugs that can be tested for treatment yet. “Remdesivir worked well in the test tube and animal models against a close relative of COVID-19,” Dr. Paul Goepfert, principal investigator at UAB. “We are very excited to have the opportunity to quickly determine if this drug will help treat hospitalized patients with COVID-1

9 here at UAB.” The National Institute of Health is sponsoring the trial to ensure the “safety and efficacy of new therapeutic agents” in adult patients diagnosed with COVID-19. The clinical trial identifier is NCT04280705. “COVID-19 is spreading rapidly across the world, and the United States now has the third highest number of cases in the world, with more than 50,000 patients,” Goepfert said, “although the first case of COVID-19 in Alabama was diagnosed for just over one week ago, we now have more than 200 cases in our condition. ”Slow dissemination ›› DOWNLOAD HERE for coronavirus CDC guidelinesFor more updates on COVID-19 on UAB, click here the WVTM 13 News app for the latest updates on COVID-19 pandemic and its impact in Alabama.

The University of Alabama at Birmingham announced on Thursday that its hospital is one of 75 locations worldwide to participate in a clinical trial for COVID-19 treatment.

The National Institute of Allergy and Infectious Diseases activated the site at Birmingham Hospital on Wednesday, which means the hospital can register in the trial immediately.

The first drug to be evaluated for treatment is remdesivir. Health officials have not released any other drugs that can be tested for treatment yet.

“Remdesivir worked well in the test tube and animal models against a close relative of COVID-19,” Dr. Paul Goepfert, principal investigator at UAB. “We are very excited to have the opportunity to quickly determine if this drug will help treat hospitalized patients with COVID-19 here at UAB.”

The National Institute of Health is sponsoring the trial to ensure the “safety and efficacy of new therapeutic agents” in adult patients diagnosed with COVID-19. The clinical trial identifier is NCT04280705.

“COVID-19 is spreading rapidly across the world, and the United States now has the third highest number of cases in the world, with more than 50,000 patients,” Goepfert said, “Although the first case of COVID-19 in Alabama was diagnosed for just over one a week ago we now have more than 200 cases in our state. “

Slow spread ›› Click here for CDC guidelines for coronavirus

For more updates on COVID-19 at UAB, click here.

Get the WVTM 13 News app for the latest updates to the COVID-19 pandemic and its impact in Alabama.


Source link